国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (2): 92-95.doi: 10.3760/cma.j.issn.1673422X.2018.02.007

• 论著 • 上一篇    下一篇

基质金属蛋白酶-9及金属蛋白酶组织抑制剂-1在肾癌中的表达及临床意义

李金涛, 李金凤   

  1. 271000 泰山医学院附属医院泌尿外科（李金涛），肿瘤内科（李金凤）
  • 出版日期:2018-02-08 发布日期:2018-02-28
  • 通讯作者: 李金涛，Email: liyun198616@126.com E-mail:liyun198616@126.com

Expressions and clinical significance of matrix metalloproteinase-9 and tissue inhibitor of metallopro-teinase-1 in renal carcinoma

Li Jintao, Li Jinfeng   

  1. Expressions and clinical significance of matrix metalloproteinase-9 and tissue inhibitor of metallopro-teinase-1 in renal carcinoma
  • Online:2018-02-08 Published:2018-02-28
  • Contact: Li Jintao E-mail:liyun198616@126.com

PDF

438

被引次数

1

摘要： 目的探讨基质金属蛋白酶9（MMP9）及金属蛋白酶组织抑制剂1（TIMP1）在肾癌中的表达及其临床意义。方法纳入我院2015年1月—2017年1月收治的45例肾癌患者列为观察组，另外纳入40例同期健康体检者作为对照组。采用酶联免疫吸附试验检测并对比两组患者外周血MMP9及TIMP1水平，并分析两者之间的相关性及与临床病理特征的关系。结果观察组患者血清MMP9表达［（461.7±53.6）pg/ml∶（142.9±31.7）pg/ml；t=32.840，P<0.001］、TIMP1表达［（387.9±11.8）pg/ml∶（136.5±21.8）pg/ml； t=13.290，P<0.001］及MMP9/TIMP1［（1.2±0.2）∶（1.1±0.1）；t=3.640，P<0.001］均显著高于对照组，差异均具有统计学意义。相关性分析结果显示观察组患者血清MMP9与TIMP1表达呈显著正相关（r=0.847，P<0.001）。观察组患者外周血MMP1、TIMP1表达水平均与淋巴结是否转移（t=2.657，P=0.011；t=4.420，P<0.001）、原发肿瘤分期（t=6.200，P<0.001；t=5.042，P<0.001）相关，而与病理分型（t=1.130，P=0.265；t=0.109，P=0.914）无关。结论肾癌患者外周血MMP9及TIMP1水平显著升高，且与患者疾病进展密切相关，可用于临床评估患者的疾病进展。

关键词: 肾肿瘤, 基质金属蛋白酶9, 淋巴转移, 基质金属蛋白酶抑制剂-1

Abstract: ObjectiveTo explore the expressions and clinical significance of matrix metalloproteinase9 (MMP9) and tissue inhibitor of metalloproteinase1 (TIMP1) in renal carcinoma. MethodsA total of 45 patients with renal carcinoma received treatment at our hospital from January 2015 to January 2017 were enrolled as observation group, and 40 healthy subjects in the same period were enrolled as control group. The expressions of MMP9 and TIMP1 in observation group and control group were tested and compared by enzymelinked immunosorbent assay. The relationship between MMP9 and TIMP1 and their correlations with the clinical pathological features were analyzed. ResultsThe serum levels of MMP9  in observation group were higher than those in control group, and the differences were significantly significant［(461.7±53.6) pg/ml vs. (142.9±31.7) pg/ml; t=32.840, P<0.001］, TIMP1 ［(387.9±11.8) pg/ml vs.(136.5±21.8) pg/ml; t=13.290, P<0.001］ and MMP9/TIMP1 ［(1.2±0.2) vs. (1.1±0.1); t=3.640, P<0.001］ . Correlation analysis showed that the serum expression level of MMP9 had significantly positive correlation with TIMP1 for patients in observation group (r=0.847, P<0.001). The serum expression levels of MMP9 and TIMP1 for patients in observation group were related to the lymph node state (t=2.657, P=0.011; t=4.420, P<0.001) and primary tumor staging (t=6.200, P<0.001; t=5.042, P<0.001), but they were not related to pathological type (t=1.130, P=0.265; t=0.109, P=0.914). ConclusionThe peripheral blood levels of MMP9 and TIMP1 are increased in patients with renal carcinoma, and they are associated with the progression of disease, which can be used to evaluate the progress of disease.

Key words: Kidney neoplasms, Matrix metalloproteinase 9, Lymphatic metastasis, Tissue inhibitor of metalloproteinase-1